Author:
El-Kadiry Abed El-Hakim,Lumbao Carlos,Salame Natasha,Rafei Moutih,Shammaa Riam
Abstract
Abstract
Background
Knee osteoarthritis (OA) is a debilitating condition affecting human body biomechanics and quality of life. Current standard care for knee OA leads to trivial improvement and entails multiple adverse effects or complications. Recently, investigational cell therapies injected intra-articularly, such as bone marrow aspirate concentrate (BMAC) and platelet-rich plasma (PRP), have shown safety and therapeutic potency providing patients with pain relief. In the current retrospective comparative study, we investigated the differences in pain and functional improvements in patients with symptomatic knee OA receiving intra-articular injections of BMAC vs PRP.
Methods
Pain and functionality scores were measured at baseline and at different time points post-injection over 12 months, using 3 self-administered, clinically validated questionnaires: the visual analogue scale (VAS) for assessing pain intensity, the knee injury and osteoarthritis outcome score (KOOS) for evaluating functionality and knee-related quality of life, and the Western Ontario and McMaster Universities Arthritis Index (WOMAC) for evaluating physical function. The repeated-measures general linear model with Sidak test for pairwise comparisons was used to investigate the influence of the treatment on the score evolution within groups (between baseline and each time point) and between groups (overall).
Results
The BMAC group (n = 26 knees) significantly improved in VAS, KOOS, and WOMAC scores between baseline and 12 months (57.4, 75.88, and 73.95% mean score improvement, respectively). In contrast, the PRP group (n = 13 knees) witnessed nonsignificant improvement in all scores. BMAC, in comparison to PRP, induced significant improvement in outcomes by 29.38% on the VAS scale, 53.89% on the KOOS scale, and 51.71% on the WOMAC scale (P < .002, P < .01, P < .011, respectively).
Conclusions
Intra-articular autologous BMAC injections are safe, effective in treating pain, and ameliorate functionality in patients with symptomatic knee OA to a greater extent than PRP injections.
Graphical abstract
Intra-articular autologous BMAC therapy is safe and provides more relief to patients with symptomatic knee osteoarthritis compared to PRP therapy.
Publisher
Springer Science and Business Media LLC
Subject
Orthopedics and Sports Medicine,Rheumatology
Reference61 articles.
1. Storheim K, Zwart JA. Musculoskeletal disorders and the global burden of disease study. Ann Rheum Dis. 2014;73:949–50.
2. Public Health Agency of Canada. Osteoarthritis in Canada. 2020. https://www.canada.ca/en/public-health/services/publications/diseases-conditions/osteoarthritis.html. Accessed 5 Jan 2021.
3. Davis A, Badley E, Mcglasson R, Alleyne Bsc J. Reducing the impact of OA: a report on the prevention and effective management in Canada. 2014. http://boneandjointcanada.com/wp-content/uploads/2014/05/BJC-OA-Meeting-Report-Final.pdf. Accessed 5 Jan 2021.
4. Manlapaz DG, Sole G, Jayakaran P, Chapple CM. Risk factors for falls in adults with knee osteoarthritis: a systematic review. PM R. 2019;11:745–57.
5. Martel-Pelletier J, Maheu E, Pelletier JP, Alekseeva L, Mkinsi O, Branco J, et al. A new decision tree for diagnosis of osteoarthritis in primary care: international consensus of experts. Aging Clin Exp Res. 2019;31:19–30. https://doi.org/10.1007/s40520-018-1077-8.
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献